AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Observation of Treatment Patterns With Lucentis in Approved Indications

Completed

Conditions: Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV

First Posted Date: 2014-07-18

Last Posted Date: 2017-03-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5778

Registration Number: NCT02194803

Locations: 🇩🇪
Novartis Investigative Site, Tübingen, Germany

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

Phase 1

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: QBW251
Drug: Placebo

First Posted Date: 2014-07-15

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT02190604

Locations: 🇬🇧
Novartis Investigative Site, Mid Glamorgan, United Kingdom

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: CLR457

First Posted Date: 2014-07-14

Last Posted Date: 2021-12-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT02189174

Locations: 🇺🇸
Massachusetts General Hospital SC-9, Boston, Massachusetts, United States
🇺🇸
Tennessee Oncology SC, Nashville, Tennessee, United States
🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

and more 1 locations

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Phase 2

Completed

Conditions: Tumors With CDK4/6 Pathway Activation

Interventions: Drug: LEE011

First Posted Date: 2014-07-11

Last Posted Date: 2019-07-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT02187783

Locations: 🇺🇸
Northern Indiana Cancer Research Consortium No. Indiana Cancer Res., South Bend, Indiana, United States
🇺🇸
New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸
PCR Oncology, Pismo Beach, California, United States

and more 58 locations

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

Phase 2

Terminated

Conditions: Tumors With Aberrations in ALK or ROS1

Interventions: Drug: Ceritinib

First Posted Date: 2014-07-10

Last Posted Date: 2021-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT02186821

Locations: 🇺🇸
Columbus Hematology and Oncology PA Columbus Hem and Onc (2), Columbus, Ohio, United States
🇺🇸
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston, Texas, United States
🇺🇸
Swedish Cancer Institute Swedish Cancer Institute, Seattle, Washington, United States

and more 18 locations

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Phase 3

Completed

Conditions: Cushings Disease

Interventions: Drug: LCI699 matching placebo
Drug: osilodrostat

First Posted Date: 2014-07-02

Last Posted Date: 2021-01-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT02180217

Locations: 🇺🇸
University of Colorado Hospital SC - LCI699C2301, Aurora, Colorado, United States
🇺🇸
Emory University School of Medicine G2304 - C2301, Atlanta, Georgia, United States
🇺🇸
Northwestern University SC - LCI699C2301, Chicago, Illinois, United States

and more 10 locations